Last reviewed · How we verify
Zolmitriptan intranasal.
At a glance
| Generic name | Zolmitriptan intranasal. |
|---|---|
| Sponsor | Parc de Salut Mar |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics in Oral and Intranasal Formulations of Zolmitriptan. (PHASE1)
- A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers (PHASE1)
- Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers (PHASE1)
- A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zolmitriptan intranasal. CI brief — competitive landscape report
- Zolmitriptan intranasal. updates RSS · CI watch RSS
- Parc de Salut Mar portfolio CI